Cramer Rosenthal Mcglynn LLC lowered its stake in Omnicell, Inc. (NASDAQ:OMCL) by 1.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 303,050 shares of the company’s stock after selling 5,990 shares during the quarter. Cramer Rosenthal Mcglynn LLC owned about 0.80% of Omnicell worth $14,698,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of OMCL. BlackRock Inc. raised its stake in Omnicell by 4.0% during the 4th quarter. BlackRock Inc. now owns 4,839,191 shares of the company’s stock valued at $234,701,000 after purchasing an additional 187,069 shares during the period. Conestoga Capital Advisors LLC raised its stake in Omnicell by 10.8% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,792,313 shares of the company’s stock valued at $86,927,000 after purchasing an additional 174,607 shares during the period. Eagle Asset Management Inc. raised its stake in Omnicell by 36.8% during the 4th quarter. Eagle Asset Management Inc. now owns 1,365,794 shares of the company’s stock valued at $66,047,000 after purchasing an additional 367,687 shares during the period. Carillon Tower Advisers Inc. bought a new stake in Omnicell during the 4th quarter valued at approximately $38,612,000. Finally, Fisher Asset Management LLC raised its stake in Omnicell by 0.3% during the 4th quarter. Fisher Asset Management LLC now owns 530,569 shares of the company’s stock valued at $25,733,000 after purchasing an additional 1,650 shares during the period.
Several analysts recently issued reports on the company. Cantor Fitzgerald reissued a “buy” rating and set a $60.00 target price on shares of Omnicell in a research note on Wednesday, December 13th. Oppenheimer reissued a “buy” rating and set a $55.00 target price on shares of Omnicell in a research note on Monday, January 29th. BidaskClub downgraded Omnicell from a “sell” rating to a “strong sell” rating in a research note on Friday, January 19th. Zacks Investment Research downgraded Omnicell from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Finally, Craig Hallum downgraded Omnicell from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $56.14.
Omnicell, Inc. (OMCL) opened at $44.55 on Wednesday. The firm has a market capitalization of $1,766.58, a P/E ratio of 267.94, a price-to-earnings-growth ratio of 3.76 and a beta of 0.75. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.28 and a current ratio of 1.73. Omnicell, Inc. has a 1-year low of $37.90 and a 1-year high of $55.40.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.02. The business had revenue of $198.26 million during the quarter, compared to analysts’ expectations of $205.50 million. Omnicell had a return on equity of 1.54% and a net margin of 2.88%. The firm’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.37 EPS. equities research analysts expect that Omnicell, Inc. will post 0.77 earnings per share for the current fiscal year.
In other Omnicell news, CFO Peter J. Kuipers sold 1,926 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $51.69, for a total transaction of $99,554.94. Following the completion of the transaction, the chief financial officer now owns 40,544 shares in the company, valued at approximately $2,095,719.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Randall A. Lipps sold 8,186 shares of the firm’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $44.21, for a total value of $361,903.06. Following the transaction, the chairman now owns 224,206 shares of the company’s stock, valued at approximately $9,912,147.26. The disclosure for this sale can be found here. Company insiders own 3.77% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Cramer Rosenthal Mcglynn LLC Sells 5,990 Shares of Omnicell, Inc. (OMCL)” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://ledgergazette.com/2018/03/14/cramer-rosenthal-mcglynn-llc-sells-5990-shares-of-omnicell-inc-omcl.html.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.